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1. Introduction 
Screening programs play a significant role in the assessment of fetal chromosomal defects 
and provide the appropriate prenatal counseling and diagnostic tests.  
Every pregnant woman has a risk that her fetus might be affected by trisomy 21. At the 
beginning of the 1980's the screening based on a woman's age was introduced. With the cut-
off age of 35 years, 5% of the pregnant women population were classified as "high-risk". 
However, only 30% of fetuses with trisomy 21 were detected in this group while the 
majority of trisomy 21 babies were born to mothers from the "low-risk" group. 
Later, biochemical screening tests in the second trimester became widely used. The test is 
based on the concentration of various fetoplacental markers in the maternal circulation: 
alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG) 
and inhibin-A. This method of screening is proved to be more effective than maternal age 
alone and at the same rate of invasive testing (about 5%) it can identify about 50 to 70% of 
the fetuses with trisomy 21 (Nicolaides KH 2004). 
In the 1990's screening tests were moved to the first trimester. The woman's age was first 
combined with sonographic measurement of fetal nuchal translucency and fetal heart rate. 
Later sonographic screening was upgraded by the measurement of maternal serum free β-
human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A 
(PAPP-A) (Wright D et al, 2008; Kagan KO et al, 2008). Fetal nuchal translucency screening 
identifies 75 to 80% of fetuses with trisomy 21 at a false positive rate of 5%. 
In the last 10 years, several additional first trimester sonographic markers have been 
described (nasal bone, tricuspid flow, ductus venosus flow) which improve the detection 
rate of chromosomal abnormalities and reduce the false positive rate. At a risk cut-off of 1 in 
100, the detection rate of trisomy 21 is about 95% at a false positive rate of 2.5%.  
The ability to achieve reliable measurements and evaluation of sonographic markers 
depends on an appropriate training of sonographers, adherence to a standard ultrasound 
technique in order to achieve uniformity of results among different operators (Nicolaides 
KH 2011). Health professionals undertaking the first trimester scan have to be adequately 
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trained and their results have to be subjected to an audit. The Fetal Medicine Foundation 
(FMF) has introduced a process of training and certification to help establish high standards 
of scanning on an international basis (www.fetalmedicine.com). 
1.1 Nuchal translucency 
Nuchal translucency (NT) is the assessment of the amount of fluid behind the neck of the 
fetus, also known as the nuchal fold. An anechoic space is visible and measurable 
sonographically in all fetuses between the 11th and 14th weeks of pregnancy (Figure 1). 
Underlying pathophysiological mechanisms for nuchal fluid collection include cardiac 
dysfunction, venous congestion in the head and neck, altered composition of the 
extracellular matrix, failure of lymphatic drainage, fetal anemia or hypoproteinemia and 
congenital infection (Nicolaides KH 2004). Accumulation of nuchal fluid decreases after the 
14th week. Enlarged NT helps us to identify the high-risk fetuses for trisomy 21 and other 
chromosomal abnormalities (Nicolaides KH et al, 1992; Nicolaides KH et al, 1994). 
NT is evaluated in fetuses with crown-rump length (CRL) range from 45 to 84 mm. The scan 
may be performed transabdominally but in some cases transvaginal approach may be 
beneficial. During the measurement, the fetus lies in a neutral position, with the head in line 
with the spine (www.fetalmedicine.com). The assessment of the NT is obtained in a mid-
sagittal view of the fetal profile. The measurements are taken with the inner border of the 
horizontal line and callipers are placed on the line that defines the NT thickness. Normally, 
NT increases with the CRL.  
 
 
Fig. 1. Measurement of nuchal translucency behind the neck of the fetus. 
1.2 Nasal bone 
The nasal root depth is abnormally short in 50% of trisomy 21 cases (Cicero S et al, 2003). 
Sonographic studies at the 15th to 22nd weeks of gestation reported that about 65% of trisomy 
21 fetuses had an absent or abnormally short nasal bone. The fetal nasal bone can be 
visualized between the 11th and 14th weeks of gestation, when CRL is between 45 and 84 
mm. The assessment of the nasal bone should be obtained in a mid-sagittal view of the fetal 
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profile (Figure 2). The image of the nose includes three lines. The top line represents the 
nasal skin, in continuity with the skin is the tip of the nose, and the bottom line represents 
the nasal bone which is thicker and more echogenic. 
 
 
Fig. 2. Assessment of the nasal bone in a mid-sagittal view of the fetal profile. 
2. Sonographic screening for trisomy 21 by maternal age, nuchal 
translucency and fetal nasal bone 
The best performance of first trimester screening is achieved by a combination of maternal 
age, serum biochemical testing and multiple sonographic markers. But Doppler assessment 
of tricuspid and ductus venosus flow can be time consuming and it requires properly 
trained sonographers. As a first stage policy the assessment only by maternal age, nuchal 
translucency and fetal nasal bone, without biochemical testing, has some advantages 
(Nicolaides KH 2011). Beside the examination of fetal anatomy which leads to early 
diagnosis of many abnormalities in all pregnancies, the major advantage is the reduction in 
the cost of screening.  The measurement of biochemical markers is undertaken only in the 
subgroup with positive first stage screening results. 
Our study reports the results of the first trimester trisomy 21 risk assessment by a 
combination of maternal age, sonographic measurement of fetal NT thickness and 
assessment of fetal nasal bone in unselected pregnancies in Slovenia.  
3. Subjects and methods 
The study included all pregnant women appointed for the first trimester ultrasound 
screening examination at a single outpatient clinic between January 4, 2005 and April 30, 
2010. Before the screening they all received counseling by their level one gynaecologists and 
an information leaflet about the ultrasound examination and the aim of screening.  
At the time of the visit, they gave details about their demographic characteristics and 
medical history, which were entered into the computer database. The examinations were 
carried out by two experienced sonographers, certified by the Fetal Medicine Foundation 
Certificate of Competence in the 11th to 14th weeks scan. 
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In the majority of the cases the examination was performed transabdominally within 20 
minutes. In less than 1% of the cases a transvaginal ultrasound examination had to be 
carried out.  
In the fetal CRL less than 45 mm, the pregnant woman was given a new appointment, while 
in the fetal CRL more than 83 mm, only a detailed ultrasound scan was performed and the 
pregnant woman received further information about the possibility of the second trimester 
biochemical test. 
For the examinations we used 2-5 MHz and 3.7-9.3 MHz transducers GE Healthcare 
Voluson 730 Pro, Milwaukee, USA, and 4–6 MHz, 4–7 MHz, 5–9 MHz and 7–9 MHz 
transducers Acuson S2000, Siemens Medical Solutions, Mountain View CA, USA. 
Only singleton pregnancies with live fetus from the 11th to 14th weeks of gestation with the 
CRL of 45-83 mm were included in the further analysis. Pregnancy outcomes were obtained 
from the participating women, referred by level one gynecologists and paediatricians. 
Karyotype results were reported by the three cytogenetic laboratories. 
3.2 Statistical methods 
Risks were calculated according to the FMF program, following the FMF guidelines 
(Snijders RJM et al, 1999; www.fetalmedicine.com). The distribution of maternal age of the 
examined women was compared to the age distribution in the pregnant population in 
Slovenia for the time interval 2005-2010 (www.stat.si).  
We calculated the sensitivity, false positive rate, positive predictive value and negative 
predictive value for a cut-off risk of 1 in 300.  We accompanied the most important results 
with a 95% confidence interval. The balance between the false positive rate and the detection 
rate was studied and the trends were inspected graphically. The cut-off risk that would 
yield 5% false positives was calculated for trisomy 21.  
Additionally, the expected numbers for the Slovene population were estimated by 
weighting the values of each woman according to the frequency of her age in the Slovene 
population.  
4. Results 
4.1 Study population 
A total of 13,535 pregnant women were offered first trimester screening for detecting fetal 
chromosomal abnormalities at a single outpatient clinic between January 4, 2005 and April 
30, 2010.  
The sample represented unselected population of pregnant women of Caucasian ethnic 
origin. Twin pregnancies (3.6% of the cases, 486 of 13,535) were excluded. All further 
analyses included 13,049 women with singleton pregnancies. 
4.2 Age distribution 
The average maternal age (at the time of screening) was 29 years (range 11 to 47, SD=3.9) 
with a distribution as shown in the Figure 3 (black columns). When compared to the age 
distribution in the pregnant population in 2005-2010 in Slovenia, the average maternal age 
was the same - 28.9 years (Figure 3, red columns). The pregnant population however varied 
more, in particular there was a larger proportion of women aged 36 and more in the Slovene 
pregnant population (10.2%) as compared to only 3.6% in our sample. The sample on the 
other hand included a considerably larger percent of the women between 26 and 30 (47.9% 
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compared to 40.6%). Only 2.5% were 37 and older compared to the 7.2% in the population of 
Slovene pregnant women. 
 
 
Fig. 3. Age distribution comparison at screening; Slovene population (red columns), our 
sample of unselected population of pregnant women (black columns). 
4.3 The screening results 
The average gestation was 12 weeks 4 days (range 11 weeks 1 day to 14 weeks 0 days). The 
average fetal CRL was 63.2 mm (range 45 to 83 mm). And the average NT thickness was 1.7 
mm (range 0.9 to 13.4 mm).  
The distribution of NT for fetal CRL in normal pregnancies and pregnancies with fetuses 
affected by chromosomal abnormalities is shown in Figure 4. The NT was above the 95th 
centile of the normal range for the CRL in 75% (15 of 20) of trisomy 21 pregnancies and in 
64% (16 of 25) pregnancies with other chromosomal abnormalities. 
At the time of testing in 3% of all pregnancies (394 of 13,049) the estimated risk for trisomy 21 
was 1 in 300 or higher, considering the calculation based on FMF program. Three hundred and 
sixty cases (2.8%) turned out to be false positive. At the invasive testing, chromosomal 
abnormalities were identified in 8.6% of high risk cases (34 of 394), which represents one case 
of fetal chromosomal abnormality detected per 12 invasive diagnostic procedures. 
4.4 Detection rate 
We detected 34 out of 45 cases with chromosomal abnormalities (75.6%), diagnosed 
prenatally or postnatally. 
Trisomy 21 was detected in 20 cases (Figure 4). Among women with an estimated risk of 1 in 
300 or higher there were 17 cases of trisomy 21. The detection rate for trisomy 21 was 85% 
(17 out of 20), the 95% confidence interval for the detection rate was [69.4, 100]. The positive 
predictive value for the trisomy 21 was 4.3% (17 of 394); and the negative predictive value 
was 99.98% (12,652 of 12,655). 
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Fig. 4. Distribution of NT (in mm) with respect to CRL (in mm) in our sample. The curves 
present the 5th, 50th and 95th centiles. 
Other chromosomal abnormalities were diagnosed in 25 cases (Figure 4). Among women 
with an estimated risk of 1 in 300 or higher there were 17 cases of other chromosomal 
abnormalities. The detection rate was 68% (17 out of 25). The 95% confidence interval for the 
detection rate was [49.7, 86.3]. The positive predictive value for the other chromosomal 
abnormalities was 4.3% (17 of 394); and the negative predictive value was 99.94% (12,647 of 
12,655). 
The diagnosed chromosomal abnormalities and their frequencies are presented in Table 1. 
The assessment of nasal bone was performed in 98.5%of the cases (12,847 out of 13,049). In 
12 cases nasal bone was absent (0.1%), and in 3 out of those 12 cases (25%), the chromosomal 
abnormality was detected. 
 
Karyotype No. 
Trisomy 21 20 
Trisomy 18 10 
Trisomy 13 2 
45,X (Turner syndrome) 3 
47,XXY 2 
Mosaic structure 3 
Unbalanced structural rearrangements 5 
Total 45 
Table 1. Chromosomal abnormalities in fetuses and newborns in our sample of 13,049 
women with singleton pregnancies. 
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4.5 The risk threshold 
The risk values of the undetected cases of trisomy 21 were as follows: 1 in 1979, 6365, 7435; 
for other chromosomal abnormalities they were 1 in 493, 872, 1102, 1279, 2016, 2180, 3816, 
6731. 
It was thus clear that a less conservative limit for probability threshold (for example 1 in 
500) would not yield different detection rate in case of trisomy 21, but would rather improve 
the detection of other chromosomal abnormalities.  
These changes are explored in Figure 5, which shows how detection rate would change by 
changing the risk threshold. The black curve shows how detection rate of trisomy 21 
changes by changing the risk threshold (value 200 implies probability threshold set at 
1/200). The red curve represents the same information for other chromosomal 
abnormalities. The numbers above the points indicate the percentage of false positives that 
would occur in our sample at that threshold. 
 
 
Fig. 5. Detection rate of trisomy 21 (black curve) and other chromosomal abnormalities (red 
curve) with respect to the risk threshold set (value 200 implies probability threshold set at 
1/200). The numbers above the points give the false positive rate.  
Inversely, Figure 6 shows the detection rate with respect to the percentage of false positives, 
the numbers above the points indicate the risk threshold (value 200 implies threshold 
1/200). 
4.6 Prediction for the Slovene population 
Since the age distribution in our sample was different from the age distribution in the 
Slovene pregnant women population, we can expect all the above results to be slightly 
different. In particular, the rate of false positives can be expected to change. Figure 7 gives 
the false positive rate in our sample with respect to calendar year and compares it to the 
predicted false positive rate in the Slovene pregnant women population.  
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Inversely, Figure 8 gives the probability threshold that would result in the 5% false positives 
rate. 
 
 
Fig. 6. Detection rate of trisomy 21 (black curve) and other chromosomal abnormalities (red 
curve) with respect to the false positive rate. The numbers above the points give the risk 
threshold (value 200 implies probability threshold set at 1/200).  
 
 
Fig. 7. The percentage of false positives in our sample (gray columns) and the predicted false 
positive rate in the Slovene pregnant women population (white columns) with respect to 
calendar year. 
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Fig. 8. The risk threshold that would result in a 5% false positive rate with respect to 
calendar year. 
 
Fig. 9. Detection rate of trisomy 21 (black curve) and other chromosomal abnormalities (red 
curve) with respect to the risk threshold set (value 200 implies probability threshold set at 
1/200) - prediction for the Slovene population. The numbers above the points give the false 
positive rate. 
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5. Discussion 
The retrospective study of the  first trimester screening for trisomy 21 in 5-year period from 
2005 to 2010 by a combination of maternal age, sonographic measurement of fetal NT 
thickness and assessment of the fetal nasal bone represented a detection rate of 85% at a 
false positive rate of 2.8%. 
5.1 Detection rate 
The findings of many studies suggest that effective first trimester screening for trisomy 21 
can be provided only by the combination of maternal age and measurement of fetal NT 
(Pajkrt E et al, 1998; Economides DL et al, 1998; Bindra R et al, 2002; Liu SS et al, 2004; 
Rozenberg P et al, 2006; Westin M et al, 2006; Czuba B et al., 2007; Kagan KO et al, 2010). At 
a risk cut-off of 1 in 100, the detection rate of trisomy 21 is about 75%, at a false positive rate 
of about 2%.  
The detection can be improved to 85% by the additional assessment of the fetal nasal bone 
and even more by the Doppler assessment of blood flow across the tricuspid valve or blood 
flow in the ductus venosus, which increased the detection rate to about 95% at a false 
positive rate of 2.5% (Kagan KO et al, 2010). The disadvantage of the Doppler assessment of 
tricuspid and ductus venosus flow is that it is time consuming and it requires appropriately 
trained sonographers (Nicolaides KH 2011). 
 
 
Fig. 10. Detection rate of trisomy 21 (black curve) and other abnormalities (red curve) with 
respect to the false positive rate - prediction for the Slovene population. The numbers above 
the points give the risk threshold (value 200 implies probability threshold set at 1/200). 
By the measurement of fetal NT thickness and the assessment of the fetal nasal bone we 
were able to achieve the expected results at a risk cut-off of 1 in 300. In our sample the 
relationship between the false positive rate and the detection rate was proved to be in line 
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with the prediction from the Nicolaides study (Nicolaides KH 2011) and highly comparable 
to other reports (Prefumo F et al, 2006; Kagan KO et al, 2010). 
Choosing sonographic assessment rather than biochemical testing as a first stage policy has 
a few advantages. In all sonographically screened pregnancies in addition to chromosomal 
markers, fetal anatomy is observed and both provide early diagnosis of many major 
abnormalities, not just in the subgroup with a positive first stage biochemical screening 
results (Nicolaides KH 2011). Further measurements of maternal serum free β-hCG and 
PAPP-A can be limited only to high risk subgroup.  
5.2 Prediction for the Slovene population 
But the trend of ageing the population of pregnant women is noticed and the false positive 
rate at the risk cut-off 1 in 300 is changing almost linearly with time (Figure 7).  
Allowing ourselves 5% false positive rate in the population, we could lower the risk limit. 
But, as our detection rate is more than adequate according to FMF guidelines, at the moment 
we have no reason to actually change it, and we believe that any such change should also be 
weighted against the risk of pregnancy loss due to invasive testing. 
Our calculations show that the FMF recommendations about the risk limit cannot be directly 
translated to our specific population distribution. We believe the limit that ensures a 5% 
false positive rate is constantly changing and could be adjusted within each country. To 
accurate the changing, the weighting could be performed using a large data set, preferably 
the data set on which the FMF algorithm was developed, using the respective population 
maternal age distribution. The only assumption needed for such estimation would be, that 
conditional on the maternal age, the NT and CRL distributions do not vary among the 
countries, which we believe is an assumption we can safely make.  
6. Conclusion 
The 11th to 14th weeks scan includes confirmation of the viability of the fetus, accurate 
dating of the pregnancy, and an early diagnosis of multiple pregnancies and identification 
of chorionicity. 
Effective screening for trisomy 21 can be achieved in the first trimester of pregnancy by a 
combination of maternal age, sonographic measurement of fetal NT thickness and 
assessment of fetal nasal bone, with detection rate of 85% at a false positive rate of less than 
3%. 
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